Health Care & Life Sciences » Biotechnology | Oncolytics Biotech Inc.

Oncolytics Biotech Inc. | Balance Sheet

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
27,222.00
16,184.50
26,077.30
14,123.10
11,836.10
13,699.90
Total Accounts Receivable
105.90
191.80
340.10
54.40
4,804.80
51.70
Other Current Assets
361.70
291.60
506.70
260.80
1,176.10
701
Total Current Assets
27,689.60
16,667.80
26,924.00
14,438.30
17,817.00
14,452.50
Net Property, Plant & Equipment
532.50
525.40
459.80
320.00
333.40
412.70
Total Assets
28,222.00
17,193.20
27,383.80
14,758.30
18,150.40
14,865.30
Accounts Payable
6,008.70
-
-
-
-
Other Current Liabilities
-
3,374.00
2,709.50
4,068.70
5,229.70
Total Current Liabilities
6,008.70
3,374.00
2,709.50
4,068.70
5,229.70
Other Liabilities
-
-
-
-
4,636.90
Total Liabilities
6,008.70
3,374.00
2,709.50
4,068.70
9,866.60
Common Equity (Total)
22,213.40
13,819.20
24,674.30
10,689.60
8,283.80
Total Shareholders' Equity
22,213.40
13,819.20
24,674.30
10,689.60
8,283.80
Total Equity
22,213.40
13,819.20
24,674.30
10,689.60
8,283.80
Liabilities & Shareholders' Equity
28,222.00
17,193.20
27,383.80
14,758.30
18,150.40

About Oncolytics Biotech

View Profile
Address
1167 Kensington Crescent NW
Calgary Alberta T2N 1X7
Canada
Employees -
Website http://www.oncolyticsbiotech.com
Updated 07/08/2019
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus called REOLYSIN. The company was founded by Matthew C.